statistiche ricercatore

Continente	#
NA - Nord America	1.778
AS - Asia	938
EU - Europa	930
Continente sconosciuto - Info sul continente non disponibili	157
SA - Sud America	118
AF - Africa	36
OC - Oceania	10
Totale	3.967

Nazione	#
US - Stati Uniti d'America	1.714
IT - Italia	360
SG - Singapore	272
VN - Vietnam	227
CN - Cina	148
DE - Germania	118
RU - Federazione Russa	106
BR - Brasile	90
HK - Hong Kong	85
GB - Regno Unito	73
IN - India	67
CA - Canada	48
FR - Francia	45
SE - Svezia	45
BD - Bangladesh	39
IE - Irlanda	35
FI - Finlandia	23
ES - Italia	20
HU - Ungheria	16
NL - Olanda	13
PL - Polonia	13
DK - Danimarca	12
TR - Turchia	12
UA - Ucraina	12
RO - Romania	11
AU - Australia	10
ET - Etiopia	10
ID - Indonesia	10
IQ - Iraq	10
KR - Corea	10
AR - Argentina	8
JP - Giappone	8
MX - Messico	8
MY - Malesia	8
ZA - Sudafrica	8
EG - Egitto	7
AT - Austria	6
CL - Cile	6
PH - Filippine	6
IR - Iran	5
PK - Pakistan	5
SA - Arabia Saudita	5
AE - Emirati Arabi Uniti	4
CO - Colombia	4
EC - Ecuador	4
GE - Georgia	4
VE - Venezuela	4
BA - Bosnia-Erzegovina	3
BE - Belgio	3
CH - Svizzera	3
KE - Kenya	3
NG - Nigeria	3
TH - Thailandia	3
UZ - Uzbekistan	3
AL - Albania	2
BG - Bulgaria	2
CR - Costa Rica	2
DZ - Algeria	2
JM - Giamaica	2
JO - Giordania	2
LT - Lituania	2
MA - Marocco	2
MD - Moldavia	2
PY - Paraguay	2
RS - Serbia	2
BY - Bielorussia	1
CI - Costa d'Avorio	1
DO - Repubblica Dominicana	1
EU - Europa	1
KG - Kirghizistan	1
NI - Nicaragua	1
NP - Nepal	1
OM - Oman	1
PA - Panama	1
PS - Palestinian Territory	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	3.812

Nome	#
Two novel SCN5A loss-of-function mutations affect patients with severe arrhytmogenic syndromes	471
Modulation of the intrinsic neuronal excitability by multifunctional liposomes tailored for treatment of Alzheimer’s disease	456
Effect of the ketogenic diet in excitable tissues	456
Channelopathies and epileptic syndromes: characterization of novel variants associated with progressive epileptic encephalopathy and in vitro validation of therapeutic approaches	445
Caveolin-3 and Caveolin-1 Interaction Decreases Channel Dysfunction Due to Caveolin-3 Mutations	429
Progressive epileptic encephalopathy associated with a novel HCN2 mutation	388
Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy	387
A novel de novo HCN2 loss-of-function variant causing developmental and epileptic encephalopathy treated with a ketogenic diet	352
Innovative therapies and nanomedicine applications for the treatment of alzheimer’s disease: A state-of-the-art (2017–2020)	307
HCN1 novel mutations in familiar generalized epilepsy	276
Totale	3.967

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	126	0	0	30	21	6	9	11	12	5	7	4	21
2022/2023	249	22	80	29	19	21	36	4	9	18	3	4	4
2023/2024	270	4	11	8	27	46	55	18	23	25	12	5	36
2024/2025	567	34	60	39	24	52	29	29	30	57	91	48	74
2025/2026	1.586	244	65	98	221	188	88	208	58	125	95	70	126
2026/2027	258	55	96	107	0	0	0	0	0	0	0	0	0
Totale													3.967

Bicocca Open Archive